How big is Maravai Lifesciences Holdings, Inc.?

As of Jun 18, Maravai Lifesciences Holdings, Inc. has a market capitalization of 532.24 million, with net sales of 241.86 million and a net profit of -289.79 million over the latest four quarters. The company's shareholder's funds are 325.29 million, and total assets amount to 1,008.24 million.

Market Cap: As of Jun 18, Maravai Lifesciences Holdings, Inc. has a market capitalization of 532.24 million, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 241.86 million and a net profit of -289.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 325.29 million, while total assets were reported at 1,008.24 million.

What does Maravai Lifesciences Holdings, Inc. do?

Maravai Lifesciences Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $47 million and a net loss of $53 million as of March 2025. The company has a market cap of $532.24 million and no dividend yield.

Overview: <BR>Maravai Lifesciences Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 47 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -53 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 532.24 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.04 <BR>Return on Equity: -34.98% <BR>Price to Book: 1.77<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Maravai Lifesciences Holdings, Inc.?

Is Maravai Lifesciences Holdings, Inc. overvalued or undervalued?

As of February 22, 2024, Maravai Lifesciences Holdings, Inc. is considered risky and overvalued with poor financial metrics and a year-to-date stock performance of -47.16%, significantly underperforming compared to the S&P 500's 12.22% return.

As of 22 February 2024, the valuation grade for Maravai Lifesciences Holdings, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.02 and an EV to Sales ratio of 2.56, which suggest that investors are paying a premium for its assets and sales relative to its peers. Additionally, the EV to EBITDA ratio stands at -23.39, highlighting significant operational challenges.<BR><BR>In comparison to its peer Zentalis Pharmaceuticals, which has a more favorable EV to EBITDA of 1.0769, Maravai's financial ratios reflect a concerning position within the Pharmaceuticals & Biotechnology industry. The company's recent stock performance has been notably poor, with a year-to-date return of -47.16% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that Maravai is struggling significantly in the current market environment.

Is Maravai Lifesciences Holdings, Inc. technically bullish or bearish?

As of September 11, 2025, Maravai Lifesciences Holdings, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while its year-to-date return is -47.16%, significantly underperforming the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Maravai Lifesciences Holdings, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly and monthly indicators such as MACD and Dow Theory show a mix of bullish and mildly bullish signals. The RSI is neutral on the weekly timeframe but bullish on the monthly. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -47.16% versus the S&P 500's 12.22%, and a one-year return of -68.56% compared to 17.14% for the benchmark.